Holding personal information in a disease-specific register: the perspectives of people with multiple sclerosis and professionals on consent and access
- 1Section of Public Health, School of Health & Related Research, University of Sheffield, Sheffield, UK
- 2Section of Health Economics and Decision Science, School of Health & Related Research, University of Sheffield, Sheffield, UK
- 3Department of Neurology, St James’s University Hospital, Leeds, UK
- 4Department of Neurology, Queen’s Medical Centre, University Hospital NHS Trust, Nottingham, UK
- 5St Lukes Hospital, Bradford, West Yorkshire, UK
- 6Clinical Neurology Research, Tamar Science Park, Plymouth, UK
- Dr W Baird, Section of Public Health, ScHARR, University of Sheffield, 219 Portobello, Sheffield S1 4DP, UK; w.o.baird{at}sheffield.ac.uk
- Received 21 March 2008
- Revised 8 September 2008
- Accepted 6 October 2008
Abstract
Objective: To determine the views of people with multiple sclerosis (MS) and professionals in relation to confidentiality, consent and access to data within a proposed MS register in the UK.
Design: Qualitative study using focus groups (10) and interviews (13).
Setting: England and Northern Ireland.
Participants: 68 people with MS, neurologists, MS nurses, health services management professionals, researchers, representatives from pharmaceutical companies and social care professionals.
Results: People with MS expressed open and altruistic views towards the use of their personal information to facilitate service provision and research, placing trust in responsible guardianship and legitimate use of their information. Participant’s proposed that people with MS should be able to select their individual level of involvement in a register using levels of consent. It was agreed that access to the register should be governed by a guardianship committee composed of a range of stakeholders. People with MS did not wish their details to be used by marketing agencies and did not consider this a legitimate use of their data. Whilst participants were positive of the role a register could play in promoting research, participants felt that access to data by pharmaceutical industries should be administered by the guardianship committee. People with MS are concerned should their employers be able to access their personal information. Professionals were more cautious than people with MS in their approach to the use of patient personal data within a register.
Conclusions: Whilst all stakeholders were positive of the benefits of an MS register, development of such a resource must incorporate robust data security and guardianship measures in order to ensure that, whilst opportunities are maximised, risks to the privacy of individuals and legal challenges to professionals are avoided.
Footnotes
-
Funding: The Multiple Sclerosis Society of Great Britain
-
Competing interests: None.
-
Ethics approval: Ethics approval was received from Leeds West NHS research ethics committee.







